CG
NTLA icon

Caprock Group’s Intellia Therapeutics NTLA Stock Holding History

Caprock Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,159
Closed -$91.3K – 1235
2025
Q4 		$91.3K Sell
10,159
-523
-5% -$7.2K ﹤0.01% 1160
2025
Q3 		$121K Buy
+10,682
New +$132K ﹤0.01% 1091
2025
Q1 		$71.6K Buy
+10,068
New +$102K ﹤0.01% 1046
2021
Q4 		– Sell
-1,514
Closed -$203K – 608
2021
Q3 		$203K Hold
1,514
– – 0.02% 501
2021
Q2 		$245K Buy
+1,514
New +$118K 0.02% 438

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Caprock Group's NTLA Position: Q1 2026 in Review

Caprock Group sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 10,159 shares — an estimated $91.3K sold.

Caprock Group first reported a position in NTLA in Q2 2021 and held it in 5 quarters. The position peaked at $245K in Q2 2021. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Caprock Group reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Caprock Group sold 10,159 Intellia Therapeutics shares in Q1 2026, an estimated $91.3K.
  • Caprock Group first reported a position in Intellia Therapeutics in Q2 2021 and held it in 5 quarters.
  • Caprock Group's Intellia Therapeutics position peaked at $245K in Q2 2021.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Caprock Group's 13F filing for Q1 2026, filed 11 May 2026.